Carl Zeiss Meditec AG : Optronik AS acquired:

Carl Zeiss Meditec strengthens business in Turkish growth market

Long-standing partner Optronik AS acquired

JENA, Germany/ ANKARA, Turkey, January 3, 2014.
Medical technology player Carl Zeiss Meditec AG has acquired its long-standing business partner, Ankara-based Optronik AS. The move is intended to enable Carl Zeiss Meditec to serve client needs even more effectively in the fast-growing Turkish market. Optronik, which has around 60 employees, was previously an exclusive distribution partner for Carl Zeiss Meditec. Integration into ZEISS's global sales, service and support network will allow for direct client care going forward.

With direct market access, ZEISS is looking to tap even more effectively into the potential of the fast-growing Turkish market. "The sustained upward trend in the Turkish market has convinced us to put our partnership with Optronik on a new footing following a positive working relationship of many years' standing, and to set the course for further growth under the ZEISS umbrella by acquiring all shares in the company as of the end of 2013," says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG.

The former partner's knowledge of the market and excellent client contacts will continue to be utilized within the new structure. All employees will be retained, and the company's head office will remain in Ankara, Turkey. The present Managing Director will also contribute to a smooth transition to the new structure by remaining as a consultant for ZEISS.

Contacts for the press:

Jann Gerrit Ohlendorf, Director Corporate Communications, Carl Zeiss Meditec AG
Tel.[phone],E-mail: [e-mail]

Sebastian Frericks, Director Investor Relations, Carl Zeiss Meditec AG

Tel.[phone],E-mail: [e-mail]

/presse

Meditec in brief Carl Zeiss Meditec AG, a TecDAX-listed company, (ISIN: DE0005313704), is a leading global player in the field of medical technology. Meditec delivers innovative technologies and applications-oriented solutions that enable physicians to enhance their patients' quality of life. The company offers total solutions, including implants and consumables, for the diagnosis and treatment of eye diseases, as well as innovative visualization solutions in microsurgery. Carl Zeiss Meditec's medical technology portfolio is rounded off by promising future-oriented technologies such as intraoperative radiation therapy. With more than 2,500 employees, the Group generated EUR 906 million in revenue in fiscal year 2012/13 (September 30).

Carl Zeiss Meditec has its corporate center in Jena, Germany. In addition to further sites in Germany, sites and subsidiaries in the USA, Japan, Spain and France employ more than 50 percent of the company's workforce. The Center for Research and Development (CARIn) in Bangalore, India, and the Carl Zeiss Innovation Center for Research and Development in Shanghai, China, give it a strong presence in these fast-growing economies. Around 35 percent of Carl Zeiss Meditec's shares are floating stock. The remaining 65 percent of the equity is held by Carl Zeiss AG, Oberkochen, a leading group of companies operating worldwide in the optical and opto-electronic industries. Carl Zeiss offers innovative solutions for the future-oriented markets Industrial Solutions, Research Solutions, Medical Technology and Consumer Optics. Carl Zeiss AG is fully owned by the Carl Zeiss Stiftung (Carl Zeiss Foundation). Further information at: www.meditec.zeiss.de